Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Market Cap	153.09B -13.2%
Revenue (ttm)	98.60B +10.3%
Net Income	13.98B +13.0%
EPS	337.33 +17.3%
Shares Out	41.38M
PE Ratio	10.97
Forward PE	13.47
Dividend	130.00 (3.51%)
Ex-Dividend Date	Sep 29, 2026

Volume	97,500
Open	3,810.00
Previous Close	3,830.00
Day's Range	3,690.00 - 3,815.00
52-Week Range	3,500.00 - 5,040.00
Beta	-0.17
Analysts	Buy
Price Target	4,566.67 (+23.42%)
Earnings Date	Nov 4, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,786
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4547

Financial Performance

In fiscal year 2026, Kissei Pharmaceutical's revenue was 97.41 billion, an increase of 10.28% compared to the previous year's 88.33 billion. Earnings were 13.78 billion, an increase of 15.20%.

Analyst Summary

According to 6 analysts, the average rating for 4547 stock is "Buy." The 12-month stock price target is ¥4,567, which is an increase of 23.42% from the latest price.

Price Target

¥4,567

(23.42% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error